Stockscreener 앱 받기
78.04
3.24%
2.45
시간 외 거래:
80.00
1.96
+2.51%
Incyte Corp 주식(INCY)의 최신 뉴스
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte: Q2 Earnings Snapshot - Huron Daily Tribune
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize
Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq
Incyte Q2 Results Top Estimates - Nasdaq
Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox
Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada
Incyte misses Q2 earnings estimates, raises Jakafi guidance - Investing.com
Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus
Incyte Reports 2025 Second Quarter Financial Results - TradingView
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Yahoo Finance
2.07%
자본화:
|
볼륨(24시간):